Overview

A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)

Status:
NOT_YET_RECRUITING
Trial end date:
2028-07-01
Target enrollment:
Participant gender:
Summary
This Phase III randomized trial, evaluates whether adding targeted radiation (SBRT) and an immunotherapy drug (Serplulimab) to standard chemotherapy (GnP) can extend the lives of patients with advanced pancreatic cancer.
Phase:
PHASE3
Details
Lead Sponsor:
West China Hospital